Published in Elife on January 18, 2016
Hallmarks of Tissue-Resident Lymphocytes. Cell (2016) 1.10
Gut microbiota and immune crosstalk in metabolic disease. Mol Metab (2016) 0.85
Development of innate lymphoid cells. Nat Immunol (2016) 0.84
Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84
Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov (2016) 0.77
Functional and phenotypic heterogeneity of group 3 innate lymphoid cells. Immunology (2016) 0.76
When Insult Is Added to Injury: Cross Talk between ILCs and Intestinal Epithelium in IBD. Mediators Inflamm (2016) 0.76
Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology (2016) 0.75
Innate lymphoid cell regulation of adaptive immunity. Immunology (2016) 0.75
In vivo multiphoton imaging of immune cell dynamics. Pflugers Arch (2016) 0.75
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature (2010) 10.34
Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature (2009) 9.71
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity (1998) 8.29
Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94
Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest (2007) 7.02
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol (2011) 6.96
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol (2011) 6.73
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature (2010) 6.44
CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med (2003) 6.00
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol (2011) 5.41
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity (2006) 5.40
CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol (2008) 5.35
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol (2008) 4.94
CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity (2010) 4.19
Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity (1997) 4.10
Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity (2008) 3.64
Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt(+) innate lymphocytes. Immunity (2010) 3.59
Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity (2008) 3.40
Type 2 innate lymphoid cells control eosinophil homeostasis. Nature (2013) 3.20
Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science (2014) 3.13
Number, size, and distribution of Peyer's patches in the human small intestine: Part I The development of Peyer's patches. Gut (1965) 3.11
Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature (2012) 2.76
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74
Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation. Immunity (2012) 2.72
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med (2013) 2.50
Sargramostim for active Crohn's disease. N Engl J Med (2005) 2.24
GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58
Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology (2008) 1.35
Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science (2015) 1.35
Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis (2008) 1.28
The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. Immunity (2015) 1.25
Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis (2010) 1.21
CCR7-dependent trafficking of RORγ⁺ ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat Commun (2015) 1.19
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One (2009) 1.16
RORγt⁺ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity (2013) 1.14
Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation. J Exp Med (2015) 1.11
IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol (2013) 1.09
Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis (2006) 1.05
Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol Cell Biol (2011) 0.96
GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen. Cell Host Microbe (2010) 0.94
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2015) 0.94
Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease. Clin Transl Gastroenterol (2012) 0.92
Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis (2012) 0.88
Opening the crypt: current facts and hypotheses on the function of cryptopatches. Trends Immunol (2009) 0.81